PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Autor: Elizabeth Hedgeman, Jon P. Fryzek, Lars Pedersen, Deirdre Cronin-Fenton, Mette Nørgaard, Torben Riis Rasmussen, Naimisha Movva, Tapashi Dalvi, Stephen Hamilton-Dutoit, Hanh Hansen, Anders Mellemgaard, Norah J. Shire

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, 16892 . https://doi.org/10.1038/s41598-021-96486-2
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, pp. 16892 . https://doi.org/10.1038/s41598-021-96486-2
Scientific Reports

Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c714e5100877d9c2cba31cc1cb53eae7
https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Autor: Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas-Socias, Sylvia F. Boj, Xavier Hernando-Momblona, Dominik Glodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink-Clements, Vanessa Zondag-van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fatrai, David Maussang, Jeroen J. Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nuciforo, Ramon Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan-Otto Attolini, Elena Sancho, Hector G. Palmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo S. Price, Robert G. J. Vries, Eduard Batlle, Mark Throsby

Publikováno v: Nature cancer, 3(4), 418-436

Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells and have predictive value supporting personalized medicine. Here we describe a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6787d32a1a24821ce4603c0851f3e6
https://pure.knaw.nl/portal/en/publications/06b7bea9-adb4-44dc-9013-631489b16e6a

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation

Autor: Saleem, H., Kulsoom Abdul, U., Küçükosmanoglu, A., Houweling, M., Cornelissen, FMG, Heiland, D.H., Hegi, M.E., Kouwenhoven, MCM, Bailey, D., Würdinger, T., Westerman, B.A.

Publikováno v: Drug resistance updates, vol. 43, pp. 29-37

Targeted therapy against driver mutations responsible for cancer progression has been shown to be effective in many tumor types. For glioblastoma (GBM), the epidermal growth factor receptor (EGFR) gene is the most frequently mutated oncogenic driver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::3d56dc6b4adf1bb1b8998c015d970023
https://serval.unil.ch/resource/serval:BIB_2AF864642976.P001/REF.pdf

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma : Increased Cell Migration and Its Association with EGFR Expression

Autor: Marco Donia, Marcell Baranyi, Dominika Rittler, Walter Berger, Eszter Molnár, József Tímár, Balázs Hegedűs, Michael Grusch, Tamás Garay

Publikováno v: Molnár, E, Garay, T, Donia, M, Baranyi, M, Rittler, D, Berger, W, Tímár, J, Grusch, M & Hegedűs, B 2019, ' Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma : Increased Cell Migration and Its Association with EGFR Expression ', International Journal of Molecular Sciences, vol. 20, no. 18, 4484 . https://doi.org/10.3390/ijms20184484
International Journal of Molecular Sciences
Volume 20
Issue 18
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4484 (2019)

Acquired resistance during BRAF inhibitor therapy remains a major challenge for melanoma treatment. Accordingly, we evaluated the phenotypical and molecular changes of isogeneic human V600E BRAF-mutant melanoma cell line pairs pre- and post-treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c940f3bdc729af27e2d11c9360835c4c
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85072142127

Differential Expression of Aquaporin-3 and Aquaporin-5 in Pancreatic Ductal Adenocarcinoma

Autor: Maria Alexandra Brito, Graça Soveral, Emanuel Vigia, Jorge Paulino, Inês Direito

Publikováno v: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP

Background and objectives: Aquaporin-5 (AQP5) and -3 (AQP3) are protein channels that showed to be up-regulated in a variety of tumors. Our goal was to investigate the expression pattern of AQP5 and AQP3 in pancreatic ductal adenocarcinomas (PDA) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f247021de06482a824310df649dc77de